Biotech Blog

Welcome to the second August 2007 edition of Carnival of Biotechnology.
International Biotechnology
The Times (UK) has a report on the UK biotech sector, calling for consolidation to overcome a lack of capital.
The Wall Street Journal has an article on Novartis’ lost patent case in India, where a patent on an improved version of Glivec (sold as [...]

Welcome to the August 2007 edition of Carnival of Biotechnology.
Industry Trends
Singapore-based ES Cell International, the company that was poised to lead in stem cell therapeutics, has abandoned its plans for stem cell therapies. Sometimes its hard for a company to live up to the high expectations they engender in their quest for financing.
In other [...]

Welcome to the June 25th 2007 edition of Carnival of Biotechnology.
Finance and business development
BusinessFund.com has a great post on 25 alternatives to venture capital — too many entrepreneurs assume that venture capital is the de facto way to fund a company, when there are many other avenues they should be exploring.
Industry Trends
As big pharma Abbott [...]

Welcome to the May 25th 2007 edition of Carnival of Biotechnology.
Finance and business development
The big news on the web is Google’s investment in 23andMe, described here by the California Biotech Law Blog.
International biotech
Business Week has an article on The Rush To Test Drugs In China. This is a story with a number of potential [...]

Welcome to the April 10, 2007 edition of Carnival of Biotechnology.
Finance and business development
On Pharma presents a report that tens of thousands of pharma sales reps are suing current and former employers for overtime – $1 billion in settlements could be at stake.
H.S. Ayoub presents The Biotech Industry: 30 Years of Failure posted [...]

The latest Carnival of Biotechnology is up at Baby Biotechs. Great job, Brian!
For more information, see the Carnival of Biotechnology Homepage, or submit a link for the next edition. Interested in hosting a future Carnival of Biotechnology? Let me know.

Investing and Clinical Trials

PharmaGossip has an illuminating excerpt from The End of Medicine describing a method to invest in drug companies as they progress through clinical trials.
Ted Love, CEO of Nuvelo Inc., explains how biotechnology companies are frequently able to recover from seemingly disastrous clinical trial failures.
Patents
When manufacturers seeking to sell generic drugs challenge patents [...]

Scientific Advances
The MaRS Blog has a captivating story of Canada’s recent major diabetes discovery. The first discovery, in 1920, elucidated insulin’s central role in diabetes. The most recent discovery, also from the University of Toronto, has found a strong link between diabetes, pain nerves, and inflammation. Researchers were able to prevent and even reverse diabetes [...]

This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion, and interesting commentary on issues in commercialization
Industry Trends
Forbes presents Genentech’s Next Act. his dialogue with Genentech’s chief officers acknowledges the longshot Genentech was in its early days and plots the future paths Genentech is pursuing [...]

Lots of interesting developments since the last edition: Pfizer’s high-profile drug failiure, a new law against violent extremists, good news for Merck, and good and bad news for the biotechnology industry as a whole.
News and Trends
The Washington Times has an update on the signing of the Animal Enterprise Terrorism Act. Bolstered by recent bombings [...]